ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis

ILTOO Pharma and the MIROCALS Consortium announce the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis. ILTOO Pharma SAS today announced the signing of Licence Agreement for the development of low dose interleukin-2 as a potential treatment for Amyotrophic Lateral Sclerosis

The release as fetched from its publisher. iltoopharma.com ↗